These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23154748)

  • 1. Aggressive B-cell lymphomas: how many categories do we need?
    Said JW
    Mod Pathol; 2013 Jan; 26 Suppl 1(0 1):S42-56. PubMed ID: 23154748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
    Kodet R; Mrhalová M; Stejskalová E; Kabícková E
    Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
    Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
    Hematol Oncol; 2010 Jun; 28(2):53-6. PubMed ID: 19844983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
    Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
    Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas.
    Horn H; Kalmbach S; Wagener R; Staiger AM; Hüttl K; Mottok A; Bens S; Traverse-Glehen A; Fontaine J; Siebert R; Rosenwald A; Ott G
    Am J Surg Pathol; 2021 Mar; 45(3):356-364. PubMed ID: 33136583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
    Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective.
    Salaverria I; Siebert R
    J Clin Oncol; 2011 May; 29(14):1835-43. PubMed ID: 21482997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
    Ott G
    Br J Haematol; 2017 Sep; 178(6):871-887. PubMed ID: 28748558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
    Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
    Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
    Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
    Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
    Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
    Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
    J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
    Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
    Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
    Bellan C; Stefano L; Giulia de F; Rogena EA; Lorenzo L
    Hematol Oncol; 2009 Dec; 27(4):182-5. PubMed ID: 19670467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Grayzone lymphoma. Clinical relevance].
    Hartmann S; Hansmann ML
    Pathologe; 2010 Feb; 31(1):42-9. PubMed ID: 20013122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.